Literature DB >> 20836157

Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling.

Sabine Mumprecht1, Christian Schürch, Sandro Scherrer, Christina Claus, Adrian F Ochsenbein.   

Abstract

Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease of hematopoietic stem cells. The disease progresses after several years from an initial chronic phase to a blast phase. Leukemia-specific T cells are regularly detected in CML patients and may be involved in the immunological control of the disease. Here, we analyzed the role of leukemia-specific CD8(+) T cells in CML disease control and the mechanism that maintains CD8(+) T-cell immunosurveillance in a retroviral-induced murine CML model. To study antigen-specific immune responses, the glycoprotein of the lymphocytic choriomeningitis virus was used as model leukemia antigen. Leukemia-specific CTL activity was detectable in vivo in CML mice and depletion of CD8(+) T cells rapidly led to disease progression. CML-specific CTL were characterized by the expression of the IL-7 receptor α-chain. In addition, leukemia cells produced IL-7 that was crucial for the maintenance of leukemia-specific CTL and for disease control. Therefore, CML cells maintain the specific CD8(+) T-cell-mediated immune control by IL-7 secretion. This results in prolonged control of disease and probably contributes to the characteristic chronic phase of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20836157     DOI: 10.1002/eji.201040404

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

2.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Leukemia's Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy.

Authors:  Jaquelyn T Zoine; Sarah E Moore; M Paulina Velasquez
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

4.  Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

Authors:  Christian Schürch; Carsten Riether; Michael A Amrein; Adrian F Ochsenbein
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

Review 5.  Regulation of hematopoietic and leukemic stem cells by the immune system.

Authors:  C Riether; C M Schürch; A F Ochsenbein
Journal:  Cell Death Differ       Date:  2014-07-04       Impact factor: 15.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.